Chronic Myelogenous Leukemia (cml) Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
  • Hematologic Malignancies
  • +16 more
  • A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
  • Birmingham, Alabama
  • +138 more
2022-03-17
Mar 17, 2022
M
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Active, not recruiting
  • Acute Leukemia
  • +3 more
  • Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
  • +5 more
  • Birmingham, Alabama
  • +38 more
2021-10-25
Oct 25, 2021
G
Phase I Study of Milatuzumab for Graft Versus Host Disease - 2015
Terminated
  • GVHD (Acute or Chronic)
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-08-12
Aug 12, 2021
N
Nilotininb, for Patients With CML-CP, CML-AP, or CML-BC
Available
  • Chronic Myelogenous Leukemia (CML)
  • Auchenflower, Queensland, Australia
  • +21 more
2021-08-16
Aug 16, 2021
W
Unrelated Umbilical Cord Blood (UBC)Transplantation - 2021
Completed
Has Results
  • Chronic Myelogenous Leukemia (CML)
  • +8 more
  • umbilical cord blood (UCB)
  • Morgantown, West Virginia
    West Virginia University Hospitals Mary Babb Randolph Cancer Cen
2021-06-07
Jun 7, 2021
G
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS)
Active, not recruiting
  • Hematological Malignancies
  • +6 more
  • NiCord® (omidubicel)
  • Cord Blood Unit
  • Los Angeles, California
  • +51 more
2021-01-07
Jan 7, 2021
M
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT - 2020
Completed
Has Results
  • Acute Myelogenous Leukemia (AML)
  • +6 more
  • ALT-803
  • Minneapolis, Minnesota
  • +2 more
2020-07-28
Jul 28, 2020
G
Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation - 2018
Completed
  • Chronic Myelogenous Leukemia (CML)
  • compliance supporting measures
  • Celle, Germany
  • +22 more
2019-12-18
Dec 18, 2019
N
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation - 2018
Completed
  • Acute Lymphoblastic Leukemia (ALL)
  • +4 more
  • CliniMACS CD34 selection system
  • ULD IL-2
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2018-07-03
Jul 3, 2018
E
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells - 2014
Terminated
Has Results
  • Leukemia, Acute
  • +6 more
  • Regulatory T-cells
  • +6 more
  • Stanford, California
    Stanford University School of Medicine
2018-06-01
Jun 1, 2018
S
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation - 2016
Terminated
Has Results
  • Acute Lymphoblastic Leukemia (ALL)
  • +6 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
2017-04-24
Apr 24, 2017
C
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs - 2016
Terminated
  • For Donors
  • +9 more
  • Los Angeles, California
  • +7 more
2017-04-06
Apr 6, 2017
M
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Unknown status
  • Chronic Kidney Disease
  • +16 more
  • Haploidentical Bone Marrow/Kidney
  • Boston, Massachusetts
    Massachusetts General Hospital
2017-03-21
Mar 21, 2017
P
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies - 2015
Completed
  • Acute Myeloid Leukemia in Remission
  • +7 more
  • Kansas City, Kansas
  • +1 more
2016-02-25
Feb 25, 2016
M
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation - 2013
Terminated
  • Acute Myelogenous Leukemia (AML)
  • +4 more
  • WT1 derived peptides
  • Durham, North Carolina
    Duke Comprehensive Cancer Center
2013-12-07
Dec 7, 2013